Pure Red Cell Aplasia Caused by Azathioprine.

Q2 Medicine

Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2020-01-01 DOI:10.2174/1871529X18666180828145818

Dimitris Kounatidis, Natalia Vallianou, Vasiliki Daskalaki, Christos Masaoutis, Evangelia Margellou, Nikos Harhalakis, Evangelos Kokkinakis

{"title":"Pure Red Cell Aplasia Caused by Azathioprine.","authors":"Dimitris Kounatidis, Natalia Vallianou, Vasiliki Daskalaki, Christos Masaoutis, Evangelia Margellou, Nikos Harhalakis, Evangelos Kokkinakis","doi":"10.2174/1871529X18666180828145818","DOIUrl":null,"url":null,"abstract":"Background: Pure Red Cell Aplasia (PRCA) is a clinical entity comprising severe normochromic normocytic anemia, reticulocytopenia, erythroblastopenia in the bone marrow, with normal leukocyte and platelets count. PRCA can be classified into congenital and acquired, with the latter characterized as idiopathic or secondary to various infections, hematological malignancies, collagen vascular diseases, thymoma, and exposure to a variety of drugs and other chemical substances.Methods: Herein, we present a female patient, who presented with PRCA due to azathioprine treatment.Results: Prompt discontinuation of the drug together with red blood cells transfusions led to complete recovery in this young patient, without any addition of immunosuppressive regimen.Conclusion: We followed 'the wait and see practice' instead of administering immunosuppression to our patient, after careful consideration and extensive consultation with our hematologists. This 'wait and see practice' proved to be effective in the long run.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"20 2","pages":"164-165"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X18666180828145818","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Pure Red Cell Aplasia (PRCA) is a clinical entity comprising severe normochromic normocytic anemia, reticulocytopenia, erythroblastopenia in the bone marrow, with normal leukocyte and platelets count. PRCA can be classified into congenital and acquired, with the latter characterized as idiopathic or secondary to various infections, hematological malignancies, collagen vascular diseases, thymoma, and exposure to a variety of drugs and other chemical substances.

Methods: Herein, we present a female patient, who presented with PRCA due to azathioprine treatment.

Results: Prompt discontinuation of the drug together with red blood cells transfusions led to complete recovery in this young patient, without any addition of immunosuppressive regimen.

Conclusion: We followed 'the wait and see practice' instead of administering immunosuppression to our patient, after careful consideration and extensive consultation with our hematologists. This 'wait and see practice' proved to be effective in the long run.

查看原文本刊更多论文

硫唑嘌呤引起的纯红细胞发育不全。

背景:纯红细胞发育不全(PRCA)是一种临床实体，包括骨髓中严重的正色正胞性贫血、网状红细胞减少症、红细胞减少症，白细胞和血小板计数正常。PRCA可分为先天性和获得性，后者的特点是特发性或继发于各种感染、血液系统恶性肿瘤、胶原血管疾病、胸腺瘤，以及暴露于各种药物和其他化学物质。方法:在此，我们报告了一位女性患者，她因硫唑嘌呤治疗而出现PRCA。结果:在没有任何免疫抑制方案的情况下，及时停药并输注红细胞使该年轻患者完全康复。结论:在与血液学专家仔细考虑和广泛咨询后，我们采用了“等待观察”的做法，而不是对患者进行免疫抑制。这种“等着瞧”的做法从长远来看是有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.